Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Buyse

Showing results (61-70 of 227) with videos related to

Pageof 23
Sort By:
Statistics in Medicine|October 13, 2005
A unifying approach for surrogate marker validation based on Prentice's criteriaAriel Alonso, Geert Molenberghs, Helena Geys, et al.
Statistical Methods in Medical Research|August 5, 2016
An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoringJulien Péron, Marc Buyse, Brice Ozenne, et al.
Revista Da Associacao Medica Brasileira (1992)|December 15, 2010
[Overall survival and other clinical outcomes in breast cancer :current situation and controversies]Karime K Machado, Artur Katz, Marc Buyse, et al.
JAMA Oncology|April 29, 2016
The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical TrialsJulien Péron, Pascal Roy, Brice Ozenne, et al.
Pharmaceutical Statistics|April 1, 2025
Detection of Outlying Correlation Coefficients in Multicenter Clinical TrialsLieven Desmet, David Venet, Laura Trotta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Statistics in oncologyStephanie R Land, Judith Abrams, Marc Buyse, et al.
Statistical Methods in Medical Research|July 7, 2017
A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analysesFederico Rotolo, Xavier Paoletti, Tomasz Burzykowski, et al.
Therapeutic Innovation & Regulatory Science|October 21, 2022
Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator OutcomesSylviane de Viron, Laura Trotta, William Steijn, et al.
Pharmaceutical Statistics|November 2, 2022
On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomesMickaël De Backer, Catherine Legrand, Julien Péron, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2019
Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLCJacek Rutkowski, Everardo D Saad, Tomasz Burzykowski, et al.
Pageof 23

Showing results (61-70 of 227) with videos related to

Sort By:
Pageof 23
Statistics in Medicine|October 13, 2005
A unifying approach for surrogate marker validation based on Prentice's criteriaAriel Alonso, Geert Molenberghs, Helena Geys, et al.
Statistical Methods in Medical Research|August 5, 2016
An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoringJulien Péron, Marc Buyse, Brice Ozenne, et al.
Revista Da Associacao Medica Brasileira (1992)|December 15, 2010
[Overall survival and other clinical outcomes in breast cancer :current situation and controversies]Karime K Machado, Artur Katz, Marc Buyse, et al.
JAMA Oncology|April 29, 2016
The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical TrialsJulien Péron, Pascal Roy, Brice Ozenne, et al.
Pharmaceutical Statistics|April 1, 2025
Detection of Outlying Correlation Coefficients in Multicenter Clinical TrialsLieven Desmet, David Venet, Laura Trotta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Statistics in oncologyStephanie R Land, Judith Abrams, Marc Buyse, et al.
Statistical Methods in Medical Research|July 7, 2017
A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analysesFederico Rotolo, Xavier Paoletti, Tomasz Burzykowski, et al.
Therapeutic Innovation & Regulatory Science|October 21, 2022
Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator OutcomesSylviane de Viron, Laura Trotta, William Steijn, et al.
Pharmaceutical Statistics|November 2, 2022
On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomesMickaël De Backer, Catherine Legrand, Julien Péron, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2019
Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLCJacek Rutkowski, Everardo D Saad, Tomasz Burzykowski, et al.
Pageof 23